Challenges of CAR-T Cell Therapy in Clinical Practice in Japan: Vein-to-Vein Interval/Unutilized Apheresis Products

DOI Web Site 18 References
  • Yagi Yu
    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • Atsuta Yoshiko
    Japanese Data Center for Hematopoietic Cell Transplantation Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine
  • Kato Koji
    Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences

Bibliographic Information

Other Title
  • 実臨床での本邦におけるCAR-T細胞療法の課題：Vein-to-vein interval/アフェレーシス産物未使用について

Search this article

Description

<p> CD19-directed chimeric antigen receptor (CAR) T-cell therapy represents a paradigm shift in the treatment of relapsed or refractory large B-cell lymphoma. However, the published real-world outcomes in European (EU) cohorts are inferior to those in the United States (US). One factor contributing to this difference is that the average time between leukapheresis and CAR T-cell infusion, known as the vein-to-vein interval, is longer for patients treated in the EU than for those treated in the US. The vein-to-vein interval in Japan is longer than that in the EU and is expected to extend beyond 2022. This presents an important issue that must be immediately addressed. After leukapheresis, some patients do not receive CAR T-cell infusion because of disease progression or complications. Unused apheresis product leads to a loss of treatment opportunities and financial burden. The optimization of hospital bed management, bridging therapies, and infection control is essential for resolving these problems.</p>

Journal

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top